Joshua W. D. Tobin

Joshua W. D. Tobin

Auto-generated profile, based on publicly available information

Joshua W. D. Tobin

Mater Research Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2018 in Blood
Verified
Journal Article
Open access
PDF file
FVFrank Vari
Frank Vari
DADavid Arpon
David Arpon
CKColm Keane
Colm Keane
MHMark S. Hertzberg
Mark S. Hertzberg
DTDipti Talaulikar
Dipti Talaulikar
MGMaher Gandhi
Maher Gandhi
Key Points: Expansion of PD-1+ CD3−CD56hiCD16-ve NK cells and PD-L1+ monocytes/macrophages is more prominent in cHL than DLBCL. PD-1 blockade reverses the immune evasion mediated by the interaction of PD-1+ NK cells and PD-L1+ monocytes/macrophages.

1 April 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CKColm Keane
Colm Keane
CGClare Gould
Clare Gould
KJKimberley Jones
Kimberley Jones
DHDavid Hamm
David Hamm
DTDipti Talaulikar
Dipti Talaulikar
MGMaher Gandhi
Maher Gandhi
Purpose: To investigate the relationship between the intra-tumoral T-cell receptor (TCR) repertoire and the tumor microenvironment (TME) in de novo diffuse large B-cell lymphoma (DLBCL) and the impact of TCR on survival. Experimental Design: We performed high-throughput unbiased TCRβ sequencing on a population-based cohort of 92 patients with DLBCL treated with conventional (i.e., non-checkpoint blockade) frontline “R-CHOP” therapy. Key immune checkpoint genes within the TME were digitally quantified by nanoString. The primary endpoints were 4-year overall survival (OS) and progression-free survival (PFS). Results: The TCR repertoire within DLBCL nodes was abnormally narrow relative to non-diseased nodal tissues (P < 0.0001). In DLBCL, a highly dominant single T-cell clone was associated with inferior 4-year OS rate of 60.0% [95% confidence interval (CI), 31.7%–79.6%], compared with 79.8% in patients with a low dominant clone (95% CI, 66.7%–88.5%; P = 0.005). A highly dominant clone also predicted inferior 4-year PFS rate of 46.6% (95% CI, 22.5%–76.6%) versus 72.6% (95% CI, 58.8%–82.4%, P = 0.008) for a low dominant clone. In keeping, clonal expansions were most pronounced in the EBV+ DLBCL subtype that is known to express immunogenic viral antigens and is associated with particularly poor outcome. Increased T-cell diversity was associated with significantly elevated PD-1, PD-L1, and PD-L2 immune checkpoint molecules. Conclusions: Put together, these findings suggest that the TCR repertoire is a key determinant of the TME. Highly dominant T-cell clonal expansions within the TME are associated with poor outcome in DLBCL treated with conventional frontline therapy. Clin Cancer Res; 23(7); 1820–8. ©2016 AACR.

28 December 2023 in British Journal of Haematology
Verified
Journal Article
Open access
KBKarolina Bednarska
Karolina Bednarska
RCRakin Chowdhury
Rakin Chowdhury
JTJoshua W. D. Tobin
Joshua W. D. Tobin
FSFiona Swain
Fiona Swain
CKColm Keane
Colm Keane
MGMaher Gandhi
Maher Gandhi
Summary: Epstein–Barr virus (EBV)‐associated lymphomas cover a range of histological B‐ and T‐cell non‐Hodgkin and Hodgkin lymphoma subtypes. The role of EBV on B‐cell malignant pathogenesis and its impact on the tumour microenvironment are intriguing but incompletely understood. Both the International Consensus Classification (ICC) and 5th Edition of the World Health Organization (WHO‐HAEM5) proposals give prominence to the distinct clinical, prognostic, genetic and tumour microenvironmental features of EBV in lymphoproliferative disorders. There have been major advances in our biological understanding, in how to harness features of EBV and its host immune response for targeted therapy, and in using EBV as a method to monitor disease response. In this article, we showcase the latest developments and how they may be integrated to stimulate new and innovative approaches for further lines of investigation and therapy.

4 May 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
CKColm Keane
Colm Keane
JTJoshua Tobin
Joshua Tobin
DTDipti Talaulikar
Dipti Talaulikar
MGMichael Green
Michael Green
PCPauline Crooks
Pauline Crooks
MGMaher Gandhi
Maher Gandhi
A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival

4 May 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SLSoi C. Law
Soi C. Law
THThanh Hoang
Thanh Hoang
KOKacey O’rOurke
Kacey O’rOurke
JTJoshua W.D. Tobin
Joshua W.D. Tobin
JGJay Gunawardana
Jay Gunawardana
MGMaher Gandhi
Maher Gandhi
Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post‐transplantation lymphoproliferative disorder ‘PTLD’) is a highly aggressive non‐Hodgkin lymphoma. It is typically treated with high‐dose methotrexate‐based regimens. Outcomes are dismal and clinical trials are lacking. It is almost always Epstein‐Barr virus (EBV)‐associated. Two patients (CA1‐2) presented with EBV‐associated PCNSL after renal transplant. CA1 was on hemodialysis, and had prior disseminated cryptococcus and pseudomonas bronchiectasis, precluding treatment with methotrexate. CA2 was refractory to methotrexate. Both were treated off‐label with the first‐generation Bruton’s tyrosine kinase inhibitor ibrutinib for 12 months. Cerebrospinal fluid penetration at therapeutic levels was confirmed in CA1 despite hemodialysis. Both patients entered remission by two months. Sequencing confirmed absence of genetic aberrations in HLA‐class I/II and antigen‐presentation/processing genes, indicating retention of the ability to present EBV‐antigens. Between weeks 10‐13, they received 3rd party EBV‐specific T cells for consolidation with no side effects. They remain in remission ≥34 months since therapy began. The strength of these findings led to an ongoing phase I study (ACTRN12618001541291).

22 June 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
KNKarthik Nath
Karthik Nath
SLSoi-Cheng Law
Soi-Cheng Law
MSMuhammed B Sabdia
Muhammed B Sabdia
JGJay Gunawardana
Jay Gunawardana
LLLilia M. de Long
Lilia M. de Long
MGMaher Gandhi
Maher Gandhi
Data on the prognostic impact of pretherapy 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) in follicular lymphoma (FL) is conflicting. The predictive utility of pretherapy total metabolic tumor volume (TMTV) and maximum standardized uptake value (SUVmax) on outcome appears to vary between regimens. Chemoimmunotherapies vary in the extent of T-cell depletion they induce. The role of intratumoral T cells on pretherapy FDG-PET parameters is undefined. We assessed pretherapy FDG-PET parameters and quantified intratumoral T cells by multiple methodologies. Low intratumoral T cells associated with approximately sixfold higher TMTV, and FL nodes from patients with high TMTV showed increased malignant B-cell infiltration and fewer clonally expanded intratumoral CD8+ and CD4+ T-follicular helper cells than those with low TMTV. However, fluorescently labeled glucose uptake was higher in CD4+ and CD8+ T cells than intratumoral B cells. In patients with FDG-PET performed prior to excisional biopsy, SUVmax within the subsequently excised node associated with T cells but not B cells. In summary, TMTV best reflects the malignant B-cell burden in FL, whereas intratumoral T cells influence SUVmax. This may contribute to the contradictory results between the prognostic role of different FDG-PET parameters, particularly between short- and long-term T-cell–depleting chemoimmunotherapeutic regimens. The impact of glucose uptake in intratumoral T cells should be considered when interpreting pretherapy FDG-PET in FL.